We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Respiratory Medicine

Journal Scan / Research · November 28, 2022

Rituximab vs Intravenous Cyclophosphamide in Patients With Connective Tissue Disease–Associated Interstitial Lung Disease in the UK

The Lancet Respiratory Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Respiratory Medicine
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial
Lancet Respir Med 2022 Nov 11;[EPub Ahead of Print], TM Maher, VA Tudor, P Saunders, MA Gibbons, SV Fletcher, CP Denton, RK Hoyles, H Parfrey, EA Renzoni, M Kokosi, AU Wells, D Ashby, M Szigeti, PL Molyneaux

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading